SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue zoomed 13.01% to Rs. 22039.20 millions for the quarter ended June 2022 as compared to Rs. 19501.60 millions during the corresponding quarter last year.Good  Net Profit growth of 25.30% reported above the corresponding previous quarter figure of Rs. 5519.70 millions to Rs. 6916.10 millioins.Operating profit for the quarter ended June 2022 rose to 9275.70 millions as compared to 8870.20 millions of corresponding quarter ended June 2021.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 22039.20 19501.60 13.01 22039.20 19501.60 13.01 88798.20 67986.10 30.61
Other Income 899.90 355.50 153.14 899.90 355.50 153.14 1112.60 625.30 77.93
PBIDT 9275.70 8870.20 4.57 9275.70 8870.20 4.57 39877.20 28832.10 38.31
Interest 1.00 2.40 -58.33 1.00 2.40 -58.33 6.50 6.90 -5.80
PBDT 9274.70 8867.80 4.59 9274.70 8867.80 4.59 39870.70 28825.20 38.32
Depreciation 834.20 730.10 14.26 834.20 730.10 14.26 3105.50 2546.50 21.95
PBT 8440.50 8137.70 3.72 8440.50 8137.70 3.72 36765.20 26278.70 39.90
TAX 1524.40 2618.00 -41.77 1524.40 2618.00 -41.77 7279.80 6731.50 8.15
Deferred Tax 148.10 223.20 -33.65 148.10 223.20 -33.65 907.80 641.00 41.62
PAT 6916.10 5519.70 25.30 6916.10 5519.70 25.30 29485.40 19547.20 50.84
Equity 530.90 530.90 0.00 530.90 530.90 0.00 530.90 530.90 0.00
PBIDTM(%) 42.09 45.48 -7.47 42.09 45.48 -7.47 44.91 42.41 5.89

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×